35868 Federal Register / Vol. 74, No. 138 / Tuesday, July 21, 2009 / Notices 

viruses. For additional information 

about EPA’s public docket visit the EPA 

Docket Center homepage at http:// 

www.epa.gov/epahome/dockets.htm. 

Docket: All documents in the docket 

are listed in the http:// 

www.regulations.gov index. Although 

listed in the index, some information is 

not publicly available, e.g., CBI or other 

information whose disclosure is 

restricted by statute. Certain other 

material, such as copyrighted material, 

will be publicly available only in hard 

copy. Publicly available docket 

materials are available either 

electronically in http:// 

www.regulations.gov or in hard copy at 

the Board of Scientific Counselors 

(BOSC), Executive Committee 

Meeting—August 6, 2009 Docket, EPA/ 

DC, EPA West, Room B102, 1301 

Constitution Ave., NW., Washington, 

DC. The Public Reading Room is open 

from 8:30 a.m. to 4:30 p.m., Monday 

through Friday, excluding legal 

holidays. The telephone number for the 

Public Reading Room is (202) 566–1744, 

and the telephone number for the ORD 

Docket is (202) 566–1752. 

FOR FURTHER INFORMATION CONTACT: The 

Designated Federal Officer via mail at: 

Lorelei Kowalski, Mail Code 8104–R, 

Office of Science Policy, Office of 

Research and Development, 

Environmental Protection Agency, 1200 

Pennsylvania Avenue, NW., 

Washington, DC 20460; via phone/voice 

mail at: (202) 564–3408; via fax at: (202) 

565–2911; or via e-mail at: 

kowalski.lorelei@epa.gov. 

SUPPLEMENTARY INFORMATION: 

General Information 

Any member of the public interested 

in receiving a draft BOSC agenda or 

making a presentation at this meeting 

may contact Lorelei Kowalski, the 

Designated Federal Officer, via any of 

the contact methods listed in the ‘‘FOR

FURTHER INFORMATION CONTACT’’ section 

above. In general, each individual 

making an oral presentation will be 

limited to a total of three minutes. 

Proposed agenda items for the 

teleconference include, but are not 

limited to: vet the draft Human Health 

program review report and discuss a 

revised process for program reviews. 

The meeting is open to the public. 

Information on Services for 

Individuals with Disabilities: For 

information on access or services for 

individuals with disabilities, please 

contact Lorelei Kowalski at (202) 564– 

3408 or kowalski.lorelei@epa.gov. To 

request accommodation of a disability, 

please contact Lorelei Kowalski, 

preferably at least ten days prior to the 

meeting, to give EPA as much time as 

possible to process your request. 

Dated: July 14, 2009. 

Mimi Dannel, 

Acting Director, Office of Science Policy. 

[FR Doc. E9–17276 Filed 7–20–09; 8:45 am] 

BILLING CODE 6560–50–P 

ENVIRONMENTAL PROTECTION 

AGENCY 

[FRL–8933–1] 

Protection of Stratospheric Ozone: 

Extension to Deadline for Critical Use 

Exemption Applications for 2012 

AGENCY: Environmental Protection 

Agency (EPA). 

ACTION: Extension to Submittal Date for 

Applications. On May 20, 2009, the 

Agency published a notice requesting 

applications for the Critical Use 

Exemption from the phaseout of methyl 

bromide for 2012 (see 74 FR 23705). 

On July 1, 2009, EPA received a letter 

from methyl bromide stakeholders 

requesting an extension to the July 20, 

2009 deadline for submitting Critical 

Use Exemption applications. The letter 

requested a deadline of August 24, 2009. 

The letter explained that additional 

time is needed by the stakeholders to 

complete their Critical Use Exemption 

applications, citing recent industry 

involvement with associated 

international meetings and national 

regulatory decisions as impeding their 

ability to devote adequate time to the 

application process. 

EPA believes that the requested 

extension is reasonable, and is granting 

the extension to all applicants. Critical 

Use Exemption Applications for 2012 

are now due to the Agency on or before 

August 24, 2009. A copy of the July 1, 

2009 letter to the Agency is available in 

the EPA Docket. 

DATES: Applications for the 2012 

Critical Use Exemption must be 

postmarked on or before August 24, 

2009. 

ADDRESSES: Applications for the methyl 

bromide Critical Use Exemption should 

be submitted in duplicate (two copies) 

by mail to: U.S. Environmental 

Protection Agency, Office of Air and 

Radiation, Stratospheric Protection 

Division, Attention Methyl Bromide 

Team, Mail Code 6205J, 1200 

Pennsylvania Ave, NW., Washington, 

DC 20460 or by courier delivery (other 

than U.S. Post Office overnight) to: U.S. 

Environmental Protection Agency, 

Office of Air and Radiation, 

Stratospheric Protection Division, 

Attention Methyl Bromide Review 

Team, 1310 L St. NW., Room 1040, 

Washington DC 20005. EPA also 

encourages users to submit their 

applications electronically to Robert 

Burchard, Stratospheric Protection 

Division, at: burchard.robert@epa.gov. If 

the application is submitted 

electronically, applicants must fax a 

signed copy of Worksheet 1 to Robert 

Burchard at 202–343–2338 by the 

application deadline. 

FOR FURTHER INFORMATION 

CONTACT: 

General Information: U.S. EPA 

Stratospheric Ozone Information 

Hotline, 1–800–296–1996; also http:// 

www.epa.gov/ozone/mbr. 

Technical Information: Bill Chism, 

U.S. Environmental Protection Agency, 

Office of Pesticide Programs (7503P), 

1200 Pennsylvania Ave., NW., 

Washington, DC 20460, 703–308–8136. 

E-mail: chism.bill@epa.gov. 

Economic Information: Elisa Rim, 

U.S. Environmental Protection Agency, 

Office of Pesticide Programs (7503P), 

1200 Pennsylvania Ave., NW., 

Washington, DC 20460, 703–308–8123. 

E-mail: rim.elisa@epa.gov. 

Regulatory Information: Robert 

Burchard, U.S. Environmental 

Protection Agency, Stratospheric 

Protection Division (6205J), 1200 

Pennsylvania Ave., NW., Washington, 

DC 20460, 202–343–9126. E-mail: 

burchard.robert@epa.gov. 

EPA Docket: The docket can be 

accessed at the http:// 

www.regulations.gov site. To obtain 

copies of materials in hard copy, please 

e-mail the EPA Docket Center: a-and-rdocket@epa.gov. The Docket ID No. for 

Critical Use Exemption Applications for 

2012 is: EPA–HQ–OAR–2009–0277. 

Dated: July 15, 2009. 

Brian J. McLean, 

Director, Office of Atmospheric Programs. 

[FR Doc. E9–17275 Filed 7–20–09; 8:45 am] 

BILLING CODE 6560–50–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[30Day-09–0666] 

Agency Forms Undergoing Paperwork 

Reduction Act Review 

The Centers for Disease Control and 

Prevention (CDC) publishes a list of 

information collection requests under 

review by the Office of Management and 

Budget (OMB) in compliance with the 

Paperwork Reduction Act (44 U.S.C. 

Chapter 35). To request a copy of these 


jlentini on DSKJ8SOYB1PROD with NOTICES
Federal Register / Vol. 74, No. 138 / Tuesday, July 21, 2009 / Notices 35869 

requests, call the CDC Reports Clearance 

Officer at (404) 639–5960 or send an email to omb@cdc.gov. Send written 

comments to CDC Desk Officer, Office of 

Management and Budget, Washington, 

DC or by fax to (202) 395–6974. Written 

comments should be received within 30 

days of this notice. 

Proposed Project 

National Healthcare Safety Network 

(NHSN) (OMB No. 0920–0666)— 

Revision—National Center for 

Preparedness, Detection, and Control of 

Infectious Diseases (NCPDCID), Centers 

for Disease Control and Prevention 

(CDC). 

Background and Brief Description 

The National Healthcare Safety 

Network (NHSN) is a system designed to 

accumulate, exchange, and integrate 

relevant information and resources 

among private and public stakeholders 

to support local and national efforts to 

protect patients and to promote 

healthcare safety. Specifically, the data 

is used to determine the magnitude of 

various healthcare-associated adverse 

events and trends in the rates of these 

events among patients and healthcare 

workers with similar risks. The data will 

be used to detect changes in the 

epidemiology of adverse events 

resulting from new and current medical 

therapies and changing risks. 

Healthcare institutions that 

participate in NHSN voluntarily report 

their data to CDC using a web browserbased technology for data entry and data 

management. Data are collected by 

trained surveillance personnel using 

written standardized protocols. This 

revision submission to OMB is a request 

to add a Hemovigilance module to the 

NHSN. This module is a response to a 

recommendation from HHS’ Advisory 

Committee on Blood Safety and 

Availability (ACBSA) to develop a 

national system for outcome 

surveillance that includes recipients of 

blood and blood products. The module 

consists of 6 additional forms: (1) The 

Hemovigilance Module Annual Survey 

(1,000 annualized burden hours); (2) the 

Hemovigilance Module Monthly 

Reporting Plan (200 annualized burden 

hours); (3) Hemovigilance Module 

Blood Produce Incident Reporting— 

Summary Data (12,000 annualized 

burden hours); (4) Hemovigilance 

Module Monthly Reporting 

Denominators (3,000 annualized burden 

hours); (5) Hemovigilance Incident form 

(6,000 annualized burden hours); and 

(6) Hemovigilance Adverse Reaction 

form (10,000 annualized burden hours). 

The Hemovigilance Module totals an 

estimated 32,200 annualized burden 

hours 

Also in this submission, CDC is also 

requesting to delete two forms currently 

approved by OMB: Implementation of 

Engineering Controls (currently 

approved for 300 burden hours) and the 

Laboratory Identified Multi-drug 

Resistant Organism (MDRO) Event 

Summary Form (currently approved for 

4,500 burden hours). These forms are no 

longer needed by the NHSN. These 

deletions total 4,800 burden hours. 

NHSN was first approved by OMB in 

2005 and a revision request was 

approved by OMB in 2008. The 2008 

revision request included modifications 

to approved forms, new modules, and 

an increase in the number of 

respondents. Later in 2008, CDC 

requested and received OMB approval 

to increase the number of respondents 

for the NHSN to 6,000 healthcare 

facilities. This change was a result of an 

increasing number of State legislatures 

requiring reporting of healthcareacquired infections by healthcare 

facilities using the NHSN. 

Participating institutions must have a 

computer capable of supporting an 

Internet service provider (ISP) and 

access to an ISP. The only other cost to 

respondents is their time to complete 

the appropriate forms. 

OMB No. 0920–0666: National 

Healthcare Safety Network (NHSN) is 

currently approved for 5,144,844 

annualized burden hours. This request 

includes a net increase of 27,400 burden 

hours (deletion of 2 forms: ¥4,800 

burden hours; new Hemovigilance 

Module: +32,200 burden hours), 

bringing the total estimated annualized 

burden hours for the entire information 

collection request to 5,172,244 hours. 

There are no additional respondents for 

this request as they are already part of 

the respondent population. 

ESTIMATE OF ANNUALIZED BURDEN HOURS

Respondents Form Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response (in 

hours) 

Infection Control Practitioner .......................... Facility Contact Information ........................... 6,000 1 10/60 

Patient Safety Component Hospital Survey .. 6,000 1 30/60 

Agreement to Participate and Consent .......... 6,000 1 15/60 

Group Contact Information ............................. 6,000 1 5/60 

Patient Safety Monthly Reporting Plan .......... 6,000 9 35/60 

Healthcare Personnel Safety Reporting Plan 600 9 10/60 

Primary Bloodstream Infection (BSI) ............. 6,000 36 30/60 

Pneumonia (PNEU)—also includes Any Patient Pneumonia Flow Diagram and Infant 

and Children Pneumonia Flow Diagram.

6,000 72 30/60 

Urinary Tract Infection (UTI) .......................... 6,000 27 30/60 

Surgical Site Infection (SSI) ........................... 6,000 27 30/60 

. Dialysis Event (DI) ......................................... 225 200 15/60 

Antimicrobial Use and Resistance (AUR)— 

Microbiology Laboratory Data.

6,000 45 3 

Antimicrobial Use and Resistance—Pharmacy Data.6,000 36 2 

Denominators for Intensive Care Unit (ICU)/ 

Other locations (Not NICU or SCA).

6,000 18 5 

Denominators for Specialty Care Area (SCA) 6,000 9 5 

Denominators for Neonatal Intensive Care 

Unit (NICU).

6,000 9 4 

Denominator for Procedure ............................ 6,000 540 8/60 

Denominator for Outpatient Dialysis .............. 225 9 5/60 

Dialysis Survey ............................................... 225 1 1 


jlentini on DSKJ8SOYB1PROD with NOTICES
35870 Federal Register / Vol. 74, No. 138 / Tuesday, July 21, 2009 / Notices 

ESTIMATE OF ANNUALIZED BURDEN HOURS—Continued 

Respondents Form Number of 

respondents 

Number of 

responses per 

respondent 

Average 

burden per 

response (in 

hours) 

List of Blood Isolates ...................................... 6,000 1 1 

Manual Categorization of Positive Blood Cultures.6,000 1 1 

Exposures to Blood/Body Fluids .................... 600 50 1 

Healthcare Personnel Post-exposure Prophylaxis.600 10 15/60 

Healthcare Personnel Demographic Data ..... 600 200 20/60 

Healthcare Personnel Vaccination History .... 600 300 10/60 

Annual Facility Survey ................................... 600 1 8 

Healthcare Worker Survey ............................. 600 100 10/60 

Healthcare Personnel Influenza Vaccination 

Form.

600 500 10/60 

Healthcare Personnel Influenza Antiviral 

Medication Administration Form.

600 50 10/60 

Pre-season Survey on Influenza Vaccination 

Programs for Healthcare Workers.

600 1 10/60 

Post-Season Survey on Influenza Vaccination Programs for Healthcare Workers.600 1 10/60 

Central Line Insertion Practices Adherence 

Monitoring Form (CLIP).

6,000 100 10/60 

Laboratory Testing ......................................... 600 100 15/60 

MDRO Prevention Process and Outcome 

Measures Monthly Monitoring Form.

6,000 24 10/60 

MDRO or CDAD Infection Event Form .......... 6,000 72 30/60 

Laboratory Identified MDRO or CDAD Event 

Form (LabID).

6,000 240 30/60 

Registration Form ........................................... 6,000 1 5/60 

High Risk Inpatient Influenza Vaccine—Summary Form Method A.6,000 5 16 

High Risk Inpatient Influenza Vaccine—Numerator Data Form Method B.2,000 250 10/60 

High Risk Inpatient Influenza Vaccine—Summary Form Method B.2,000 5 4 

High Risk Inpatient Influenza Vaccine—Denominator Data Form Method B.2,000 250 5/60 

Hemovigilance Module Annual Survey .......... 500 1 2 

Hemovigilance Module Monthly Reporting 

Plan.

500 12 2/60 

Hemovigilance Module Blood Product Incident Reporting—Summary Data.500 12 2 

Hemovigilance Module Monthly Reporting 

Denominators.

500 12 30/60 

Hemovigilance Incident .................................. 500 72 10/60 

Hemovigilance Adverse Reaction .................. 500 120 10/60 

Dated: July 13, 2009. 

Marilyn S. Radke, 

Reports Clearance Officer, Centers for Disease 

Control and Prevention. 

[FR Doc. E9–17263 Filed 7–20–09; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Centers for Disease Control and 

Prevention 

[60 Day–09–09CD] 

Proposed Data Collections Submitted 

for Public Comment and 

Recommendations 

In compliance with the requirement 

of Section 3506(c)(2)(A) of the 

Paperwork Reduction Act of 1995 for 

opportunity for public comment on 

proposed data collection projects, the 

Centers for Disease Control and 

Prevention (CDC) will publish periodic 

summaries of proposed projects. 

Alternatively, to obtain a copy of the 

data collection plans and instrument, 

call 404–639–5960 and send comments 

to Maryam I. Daneshvar, CDC Reports 

Clearance Officer, 1600 Clifton Road, 

NE., MS–D74, Atlanta, Georgia 30333; 

comments may also be sent by e-mail to 

omb@cdc.gov. 

Comments are invited on (a) whether 

the proposed collection of information 

is necessary for the proper performance 

of the functions of the agency, including 

whether the information shall have a 

practical utility; (b) the accuracy of the 

agency’s estimate of the burden of the 

proposed collection of information; (c) 

ways to enhance the quality, utility, and 

clarity of the information to be 

collected; and (d) ways to minimize the 

burden of the collection of information 

on respondents, including through the 


jlentini on DSKJ8SOYB1PROD with NOTICES